Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection

European Respiratory Journal

Volumn 35, Issue 3, 2010, Pages 619-626

  Leidl, L ^a   Mayanja Kizza, H ^b   Sotgiu, G ^c   Baseke, J ^b   Ernst, M ^a   Hirsch, C ^e   Golettie, D ^d   Toossi, Z ^e   Lange, C ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF SASSARI   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Culture filtrate protein 10; Early secretory antigenic target 6; HIV; Interferon release assay; Latent tuberculosis infection; Tuberculosis

Indexed keywords

INTERFERON; INTERFERON C; MYCOBACTERIUM ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AFRICA; ARTICLE; CD4+ T LYMPHOCYTE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; MALE; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; VIRAL LOAD;

EID: 77951184831     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00045509     Document Type: Article

References (47)

1. World Health Organization. Global Tuberculosis Control 2008: Surveillance, Planning, Financing. World Health Organization, Geneva, 2008.
2. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune response to Mycobacterium tuberculosis. A TBNET consensus statement. Eur Respir J 2009; 33: 956-973.
3. Corbett EL, Steketee RW, ter Kuile FO, et al. HIV-1/AIDS and the control of other infectious diseases in Africa. Lancet 2002; 359: 2177-2187.
4. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol Infect 1997; 119: 183-201.
5. Dolin PJ, Raviglione MC, Kochi A. Global tuberculosis incidence and mortality during 1990-2000. Bull World Health Organ 1994; 72: 213-220.
6. Maartens G, Wilkinson RJ. Seminar: tuberculosis. Lancet 2007; 370: 230-243.
7. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188: 1146-1155.
8. Bates I, Fenton C, Gruber J, et al. Vulnerability to malaria, tuberculosis, and HIV/AIDS infection and disease. Part 1: determinants operating at individual and household level. Lancet Infect Dis 2004; 4: 267-277.
9. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J Infect Dis 2005; 191: 150-158.
10. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. Aids 2005; 19: 2109-2116.
11. Chaisson RE, Martinson NA. Tuberculosis in Africa: combating an HIV-driven crisis. N Engl J Med 2008; 358: 1089-1092.
12. Chin DP, Osmond D, Page-Shafer K. Reliability of anergy skin testing in persons with HIV infection. The pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1996; 153: 1982-1984.
13. Caiaffa WT, Graham NM, Galai N, et al. Instability of delayed-type hypersensitivity skin test anergy in human immunodeficiency virus infection. Arch Intern Med 1995; 155: 2111-2117.
14. Duncan LE, Elliott AM, Hayes RJ, et al. Tuberculin sensitivity and HIV-1 status of patients attending a sexually transmitted diseases clinic in Lusaka, Zambia: a cross-sectional study. Trans R Soc Trop Med Hyg 1995; 89: 37-40.
15. Markowitz N, Hansen NI, Wilcosky TC. Tuberculin and anergy testing in HIV-seropositive and HIV-seronegative persons. Pulmonary Complications of HIV Infection Study Group. Ann Intern Med 1993; 119: 185-193.
16. Chapman AL, Munkanta M, Wilkinson KA, et al. Rapid detection of active and latent tuberculosis infection in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells. Aids 2002; 16: 2285-2293.
17. Dheda K, Lalvani A, Miller RF, et al. Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. Aids 2005; 19: 2038-2041.
18. Lalvani A, Nagvenkar P, Udwadia Z, et al. Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 2001; 183: 469-477.
19. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-γ release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175: 737-742.
20. Lawn SD, Bangani N, Vogt M, et al. Utility of interferon-γ ELISPOT assay responses in highly tuberculosis-exposed patients with advanced HIV infection in South Africa. BMC Infect Dis 2007; 7: 99.
21. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-520.
22. World Health Organization. Global Tuberculosis Control: Uganda. 2007. World Health Organization Geneva.
23. Sokal JE. Measurement of delayed skin-test responses. N Engl J Med 1975; 293: 501-502.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
25. Altman DG. Practical statistics for medical research. Chapman and Hall, London, 1991.
26. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch Intern Med 2003; 163: 1009-1021.
27. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007; 196: 15-27.
28. Nunn P, Reid A, De Cock KM. TB and HIV Infection: the global setting. J Infect Dis 2007; 196: 5-14.
29. Lee JY, Choi HJ, Park IN, et al. Comparison of two commercial interferon-c assays for diagnosing Mycobacterium tuberculosis infection. Eur Respir J 2006; 28: 24-30.
30. Antonucci G, Girardi E, Raviglione MC, et al. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995; 274: 143-148.
31. Sarrazin H, Wilkinson KA, Andersson J, et al. Association between tuberculin skin test reactivity, the memory CD4 cell subset, and circulating FoxP3-expressing cells in HIV-infected persons. J Infect Dis 2009; 199: 702-710.
32. Richeldi L, Losi M, D'Amico R, et al. Performance of tests for latent tuberculosis in different groups of immunocompromised patients. Chest 2009; 136: 198-204.
33. Talati NJ, Seybold U, Humphrey B, et al. Poor concordance between interferon-γ release assays and tuberculin skin tests in diagnosis of latent tuberculosis infection among HIV-infected individuals. BMC Infect Dis 2009; 9: 15.
34. Stephan C, Wolf T, Goetsch U, et al. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. Aids 2008; 22: 2471-2479.
35. Mandalakas AM, Hesseling AC, Chegou NN, et al. High level of discordant IGRA results in HIV-infected adults and children. Int J Tuberc Lung Dis 2008; 12: 417-423.
36. Day CL, Mkhwanazi N, Reddy S, et al. Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral load in HIV-1-infected persons. J Infect Dis 2008; 197: 990-999.
37. Hammond AS, McConkey SJ, Hill PC, et al. Mycobacterial T cell responses in HIV-infected patients with advanced immunosuppression. J Infect Dis 2008; 197: 295-299.
38. Karam F, Mbow F, Fletcher H, et al. Sensitivity of IFN-γ release assay to detect latent tuberculosis infection is retained in HIV-infected patients but dependent on HIV/AIDS progression. PLoS ONE 2008; 3: e1441.
39. Aabye MG, Ravn P, PrayGod G, et al. The impact of HIV infection and CD4 cell count on the performance of an interferon γ release assay in patients with pulmonary tuberculosis. PLoS ONE 2009; 4: e4220.
40. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-γ release assay in Zambian adults with active tuberculosis. PLoS ONE 2008; 3: e2489.
41. Vincenti D, Carrara S, Butera O, et al. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 2007; 150: 91-98.
42. Hirsch CS, Ellner JJ, Blinkhorn R, et al. In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. Proc Natl Acad Sci USA 1997; 94: 3926-3931.
43. Hirsch CS, Hussain R, Toossi Z, et al. Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon γ production. Proc Natl Acad Sci USA 1996; 93: 3193-3198.
44. Vanham G, Toossi Z, Hirsch CS, et al. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuber Lung Dis 1997; 78: 145-158.
45. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-γ test. Respir Res 2006; 7: 56.
46. Jones S, de Gijsel D, Wallach FR, et al. Utility of QuantiFERON-TB Gold in-tube testing for latent TB infection in HIV-infected individuals. Int J Tuberc Lung Dis 2007; 11: 1190-1195.
47. Hill PC, Jackson-Sillah DJ, Fox A, et al. Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS ONE 2008; 3: e1379.